Reuters logo
BRIEF-Synairgen announces additional positive data from LOXL2 inhibitor programme
March 10, 2017 / 8:49 AM / 6 months ago

BRIEF-Synairgen announces additional positive data from LOXL2 inhibitor programme

March 10 (Reuters) - Synairgen Plc

* Additional positive data in lung fibrosis

* Oral administration of one of the compounds significantly inhibited cross-link formation, reduced fibrosis score and improved lung function

* Successful completion of toxicology studies will enable commencement of phase I clinical trials in h2 this year as planned

* Expect to commence phase I clinical trials of LOXL2 inhibitor during second half of 2017

* Expect to hear outcome of Astrazeneca phase II trial of interferon beta during first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below